Curis to Report Q3 Results Nov. 12 as AML Funding Gap Persists
Image
LEXINGTON, Mass. – November 05, 2026 -- Curis, Inc. (NASDAQ: CRIS) will report third-quarter 2026 financial and operating results on Thursday, November 12, 2026, at 4:00 p.m. ET, with a conference call and webcast following at 4:30 p.m. ET.
Curis ties acute myeloid leukemia expansion to new funding
The company's monotherapy and combination studies of emavusertib in acute myeloid leukemia (AML) are substantially complete. Curis plans to continue AML development only with additional funding, which makes the November 12 update a checkpoint on its financial position.